Skip to content
10-Q

Quarterly Report

Maravai LifeSciences Holdings, Inc. MRVI

0001823239-25-000120

← back to feed
Filed
Nov 7, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2025 · Sep 30, 2025 144.68M sh
Shares Diluted Q3 2025 · Sep 30, 2025 144.12M sh
Shares Diluted Q3 2025 · Sep 30, 2024 141.56M sh
Shares Diluted Q3 2025 · Sep 30, 2024 136.6M sh
Capex Q3 2025 · Sep 30, 2025 $11.04M
Capex Q3 2025 · Sep 30, 2024 $23.81M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$34.81M
Operating Cash Flow Q3 2025 · Sep 30, 2024 $22.1M
Long Term Debt Q3 2025 · Sep 30, 2025 $287.38M
Long Term Debt Q3 2025 · Dec 31, 2024 $290.49M
Short Term Debt Q3 2025 · Sep 30, 2025 $5.44M
Short Term Debt Q3 2025 · Dec 31, 2024 $5.44M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $243.57M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $322.4M
Stockholders Equity Q3 2025 · Sep 30, 2025 $245.44M
Stockholders Equity Q3 2025 · Dec 31, 2024 $325.29M
Current Liabilities Q3 2025 · Sep 30, 2025 $61.57M
Current Liabilities Q3 2025 · Dec 31, 2024 $56.97M
Total Liabilities Q3 2025 · Sep 30, 2025 $417.33M
Total Liabilities Q3 2025 · Dec 31, 2024 $431.04M
Current Assets Q3 2025 · Sep 30, 2025 $325.87M
Current Assets Q3 2025 · Dec 31, 2024 $429.15M
Total Assets Q3 2025 · Sep 30, 2025 $849.19M
Total Assets Q3 2025 · Dec 31, 2024 $1.01B
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.18
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.66
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$0.68
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.87
Eps Basic Q3 2025 · Sep 30, 2025 −$0.18
Eps Basic Q3 2025 · Sep 30, 2025 −$0.66
Eps Basic restated Q3 2025 · Sep 30, 2024 −$0.68
Eps Basic Q3 2025 · Sep 30, 2024 −$0.87
Sga Expense Q3 2025 · Sep 30, 2025 $35.4M
Sga Expense Q3 2025 · Sep 30, 2025 $113.54M
Sga Expense Q3 2025 · Sep 30, 2024 $39.09M
Sga Expense Q3 2025 · Sep 30, 2024 $120.53M
Rd Expense Q3 2025 · Sep 30, 2025 $3.84M
Rd Expense Q3 2025 · Sep 30, 2025 $13.61M
Rd Expense restated Q3 2025 · Sep 30, 2024 $4.7M
Rd Expense Q3 2025 · Sep 30, 2024 $14.66M
Net Income Q3 2025 · Sep 30, 2025 −$25.56M
Net Income Q3 2025 · Sep 30, 2025 −$95.09M
Net Income restated Q3 2025 · Sep 30, 2024 −$97.07M
Net Income restated Q3 2025 · Sep 30, 2024 −$118.94M
Operating Income Q3 2025 · Sep 30, 2025 −$41.03M
Operating Income Q3 2025 · Sep 30, 2025 −$156.47M
Operating Income restated Q3 2025 · Sep 30, 2024 −$165.61M
Operating Income restated Q3 2025 · Sep 30, 2024 −$197.92M
Gross Profit Q3 2025 · Sep 30, 2025 $5.66M
Gross Profit Q3 2025 · Sep 30, 2025 $21.15M
Gross Profit Q3 2025 · Sep 30, 2024 $32.23M
Gross Profit Q3 2025 · Sep 30, 2024 $88.92M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $35.98M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $114.73M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $36.79M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $113.71M
Revenue Q3 2025 · Sep 30, 2025 $41.63M
Revenue Q3 2025 · Sep 30, 2025 $135.88M
Revenue restated Q3 2025 · Sep 30, 2024 $69.03M
Revenue restated Q3 2025 · Sep 30, 2024 $202.63M